Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Niessen

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Blood|June 25, 2011
The Notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic developmentKyle Niessen, Gu Zhang, John Brady Ridgway, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 2005
Minimal contribution of marrow-derived endothelial precursors to tumor vasculatureBruno Larrivée, Kyle Niessen, Ingrid Pollet, et al.
Physiological Genomics|December 3, 2009
Genomic analysis distinguishes phases of early development of the mouse atrio-ventricular canalPavle Vrljicak, Alex C Y Chang, Olena Morozova, et al.
Nature|February 12, 2010
Chronic DLL4 blockade induces vascular neoplasmsMinhong Yan, Christopher A Callahan, Joseph C Beyer, et al.
The EMBO Journal|March 26, 2013
OTUB1 modulates c-IAP1 stability to regulate signalling pathwaysTatiana Goncharov, Kyle Niessen, Maria Cristina de Almagro, et al.
Circulation Research|February 28, 2004
Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformationMichela Noseda, Graeme McLean, Kyle Niessen, et al.
Developmental Cell|August 16, 2011
Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclaseAlex C Y Chang, YangXin Fu, Victoria C Garside, et al.
Cell Reports|July 7, 2021
Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapyEswari Dodagatta-Marri, Hsiao-Yen Ma, Benjia Liang, et al.
Neurology|August 9, 2013
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Blood|June 25, 2011
The Notch1-Dll4 signaling pathway regulates mouse postnatal lymphatic developmentKyle Niessen, Gu Zhang, John Brady Ridgway, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 24, 2005
Minimal contribution of marrow-derived endothelial precursors to tumor vasculatureBruno Larrivée, Kyle Niessen, Ingrid Pollet, et al.
Physiological Genomics|December 3, 2009
Genomic analysis distinguishes phases of early development of the mouse atrio-ventricular canalPavle Vrljicak, Alex C Y Chang, Olena Morozova, et al.
Nature|February 12, 2010
Chronic DLL4 blockade induces vascular neoplasmsMinhong Yan, Christopher A Callahan, Joseph C Beyer, et al.
The EMBO Journal|March 26, 2013
OTUB1 modulates c-IAP1 stability to regulate signalling pathwaysTatiana Goncharov, Kyle Niessen, Maria Cristina de Almagro, et al.
Circulation Research|February 28, 2004
Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformationMichela Noseda, Graeme McLean, Kyle Niessen, et al.
Developmental Cell|August 16, 2011
Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclaseAlex C Y Chang, YangXin Fu, Victoria C Garside, et al.
Cell Reports|July 7, 2021
Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapyEswari Dodagatta-Marri, Hsiao-Yen Ma, Benjia Liang, et al.
Neurology|August 9, 2013
L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patientsNicholas Schwab, Tilman Schneider-Hohendorf, Vilmos Posevitz, et al.
Pageof 2